Phase 1 N=27 CampETEC Hyperimmune Bovine Colostrum (HBC)
Healthy Volunteer
Primary: Incidence of Adverse Events — 1; 1; 0; 1 events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=42 LMN-101 in a Campylobacter Human Challenge Model
Campylobacter Infections
Primary: Number of Participants With Solicited or Unsolicited Adverse Events — 15; 16; 17; 16 Participants
Phase 3 N=30 Efficacy of Rifaximin in Preventing Campylobacteriosis
Dysentery · Diarrhea · Enteric Campylobacteriosis
Primary: Campylobacteriosis — 13; 11 Participants
Phase 1 N=48 Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea
Campylobacter Infection
Primary: Safety: Presence of Related/Not Related Local and/or Systemic Reactogenicity (Adverse Events) — 10; 17; 10; 29 Adverse Events
N/A N=4,561 Chronic Gastrointestinal Sequelae of an Acute Outbreak of Bacterial Gastroenteritis in Walkerton Ontario
Irritable Bowel Syndrome
Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants
N/A N=67 Epidemiology Non-cholera Vibrio Infections
Vibrio Infections
Primary: Number of Participants With Diagnosed Non-cholerae or Non-O1/O139 Vibrio Infection — 20; 7; 2; 18 Participants
N/A N=45 Clinical Experiment of Helicobacter Pylori Transmission
Infection · Achlorhydria
Primary: Development of Diarrhea — 5; 6 participants
Phase 3 N=259 Antibiotic Safety (SCAMP)
Complicated Intra Abdominal Infections
Primary: Death — 5; 5; 7; 1 Participants
Phase 3 N=333 Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens
Complicated Urinary Tract Infection · Complicated Intra-abdominal Infection
Primary: Clinical Response at Test of Cure (TOC) in Microbiological Modified Intent-to-treat (mMITT) Analysis Set — 6; 8; 129; 132 Participant
N/A N=3,153 COMBACTE-CDI Understanding the Burden of C. Difficile Infection
Clostridium Difficile Infection
Primary: The Number of Cases of CDI — 103; 0 Participants
N/A N=983 Probiotics and Infections in Conscripts in Military Service
Respiratory Tract Infections · Gastrointestinal Diseases · Asthma Exacerbations
Primary: Number of Sick Days — p=< 0.05
Phase 4 N=200 Ciprofloxacin for Prevention of BK Infection
BK Virus Infection
Primary: Number of Patients Developing BK Infection at 6 Months Post-transplant — 25; 5 Participants
N/A N=60 Improvements Through the Use of a Rapid Multiplex PCR Enteric Pathogen Detection Kit in Children With Hematochezia
Diarrhea Bloody
Primary: Blood Test Performance — 18; 17 Participants
Phase 4 N=232 Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection
Helicobacter Infection
Primary: Number of Participants in Which H. Pylori Was Eradicated — 92; 95 participants
Phase 3 N=152 Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
Healthcare-associated Pneumonia (HCAP) · Bloodstream Infections (BSI) · Hospital Acquired Pneumonia (HAP)
Primary: Percentage of Participants With Clinical Cure at Test of Cure (TOC) in Participants With HAP/VAP/HCAP or BSI/Sepsis — 50.0; 52.6; 43.5; 42.9 percentage of participants
Phase 2 N=204 Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections
Complicated Intra-abdominal Infections
Primary: Number of Participants With Clinical Response at the Test of Cure (TOC) Visit — 62; 71 participants
N/A N=33 Enhanced, Personalized and Integrated Care for Infection Management at the Point-Of-Care
Antibiotic Resistant Infection · Infection
Primary: Percentage of Appropriate Antimicrobial Prescriptions Recommended — 90 percentage of prescriptions appropriate
Phase 1 N=59 Safety and Immunogenicity of CJCV2 With and Without ALFQ
Campylobacter Infection
Primary: Number and Percentage of Participants With Solicited Local Adverse Events (AEs) Through 7 Days After Each Study Vaccination — 4; 9; 2; 10 Participants